For example, though treating a Hodgkin Lymphoma cell line with siRNAs to PTPRK increases cell viability [41], the expression of EBNA1 in an EBV-positive Hodgkin Lymphoma cell seems unlikely to provide such a selective advantage because EBV fails to provide these cells sufficient selective advantages to be maintained in them as they proliferate in culture (ibid).EBV plasmids are generally lost from explanted Hodgkin’s Lymphomas. Here, PTPRK is linked to Hodgkins lymphoma.